<DOC>
	<DOCNO>NCT02937402</DOCNO>
	<brief_summary>This pilot clinical trial study well bronchoscopy bronchoalveolar lavage work identify biomarkers response immune checkpoint inhibitor patient non-small cell small cell lung cancer . Bronchoscopy use thin , tube-like instrument insert nose mouth view inside trachea , air passage , lung . Bronchoalveolar lavage wash bronchi alveoli flushing fluid . Bronchoscopy bronchoalveolar lavage may make easy help determine biomarkers present cancer others help determine individual great less chance benefiting immunotherapy .</brief_summary>
	<brief_title>Bronchoscopy With Bronchoalveolar Lavage Identifying Biomarkers Response Immune Checkpoint Inhibitors Patients With Non-small Cell Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To discover predictive immune biomarkers response immune checkpoint inhibitor therapy individual primary lung cancer . SECONDARY OBJECTIVES : I . To determine biomarkers may predictive treatment related adverse event , specifically pneumonitis . II . To elucidate lung immunologic microenvironment perform single cell analysis addition mass cytometry ( Cytof ) cell bronchoalveolar lavage . OUTLINE : Patients undergo bronchoscopy bronchoalveolar lavage 45 minute . After completion study , patient follow 3 , 6 , 12 , 24 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Confirmed diagnosis nonsmall cell lung cancer ( NSCLC ) small cell lung cancer ( SCLC ) Candidate undergo immune checkpoint inhibitor ( ICI ) therapy SCLC NSCLC ( ICI line chemotherapy acceptable ) deem individual 's treat oncologist Enrollment study may occur tandem clinical therapeutic trial occur Vanderbilt University Medical Center ( VUMC ) long trial violate protocol inclusion criterion study Coagulopathy international normalize ratio ( INR ) &gt; 2.0 Coagulopathy platelet ( Plt ) &lt; 10 k Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Subjects active recent history know suspect autoimmune disease recent history syndrome require systemic corticosteroids/immunosuppressive medication Respiratory failure require great 6 Lpm supplemental oxygen ( O2 ) nasal cannula mechanical ventilation within past six week Inability perform inform consent due medical psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>